Vivantis

Vivantis is a global biotechnology company focused on the discovery, development, and commercialization of innovative therapies for serious diseases. Founded in 2003, the company is headquartered in South San Francisco, California. Vivantis operates through two primary business units: Vivantis Oncology and Vivantis Neuroscience.

Vivantis Oncology is dedicated to developing targeted therapies for cancer. The company's portfolio includes several clinical-stage programs targeting various types of cancer, with a focus on solid tumors and hematologic malignancies. One of their notable products is imetelstat, an oral, selective, and reversible inhibitor of the enzyme IDO1, which is currently in Phase 3 clinical trials for the treatment of advanced melanoma.

Vivantis Neuroscience focuses on the development of therapies for neurological disorders. The company's pipeline includes several investigational drugs targeting conditions such as Alzheimer's disease, Parkinson's disease, and multiple sclerosis. One of their key programs is the development of a novel therapy for Alzheimer's disease, which is in Phase 2 clinical trials.

Vivantis has a strong research and development pipeline, with a significant investment in early-stage research and preclinical development. The company collaborates with academic institutions, research organizations, and pharmaceutical partners to advance its drug discovery efforts. Vivantis is publicly traded on the NASDAQ under the ticker symbol VVNT.

The company's mission is to improve the lives of patients by delivering innovative therapies that address unmet medical needs. Vivantis aims to achieve this through its commitment to scientific excellence, clinical innovation, and a patient-centric approach.